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Chronic obstructive pulmonary disease
ABSTRACT
Introduction Population-based epidemiological 
evidence suggests that exposure to ambient air 
pollutants increases hospitalisations and mortality 
from chronic obstructive pulmonary disease (COPD), 
but less is known about the impact of exposure to air 
pollutants on patient-reported outcomes, morbidity and 
progression of COPD.
Methods and analysis The Subpopulations 
and Intermediate Outcome Measures in COPD 
(SPIROMICS) Air Pollution Study (SPIROMICS AIR) 
was initiated in 2013 to investigate the relation between 
individual-level estimates of short-term and long-
term air pollution exposures, day-to-day symptom 
variability and disease progression in individuals 
with COPD. SPIROMICS AIR builds on a multicentre 
study of smokers with COPD, supplementing it with 
state-of-the-art air pollution exposure assessments 
of fine particulate matter, oxides of nitrogen, ozone, 
sulfur dioxide and black carbon. In the parent study, 
approximately 3000 smokers with and without airflow 
obstruction are being followed for up to 3 years for 
the identification of intermediate biomarkers which 
predict disease progression. Subcohorts undergo 
daily symptom monitoring using comprehensive daily 
diaries. The air monitoring and modelling methods 
employed in SPIROMICS AIR will provide estimates of 
individual exposure that incorporate residence-specific 
infiltration characteristics and participant-specific 
time-activity patterns. The overarching study aim is to 
understand the health effects of short-term and long-
term exposures to air pollution on COPD morbidity, 
including exacerbation risk, patient-reported outcomes 
and disease progression.
Ethics and dissemination The institutional review 
boards of all the participating institutions approved 
the study protocols. The results of the trial will be 
presented at national and international meetings and 
published in peer-reviewed journals.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is a leading cause of death world-
wide, and its prevalence is expected to 
increase.1 Individuals with COPD suffer high 
morbidity, including poor quality of life, 
activity limitation and exacerbations. A better 
understanding of contributing factors to the 
development, progression and burden of this 
pervasive disease is critical. COPD is largely 
attributable to the total burden of toxic gases 
and particles that individuals inhale during 
their lifetimes. While the primary expo-
sure in the USA is cigarette smoke, ambient 
air pollution, including particulate matter 
air pollution, has also been associated with 
lower lung function and higher incidence of 
COPD.2 Population-based epidemiological 
evidence suggests that exposure to ambient 
air pollutants increases hospitalisations and 
mortality from COPD,2 but little is known 
about the impact of exposure to air pollutants 
on the progression of COPD. Both outdoor 
and indoor air pollution may accelerate 
lung function loss in individuals with COPD, 
impact health status and lead to exacerbations 
that represent substantial patient burden but 
do not require hospitalisation.
The Subpopulations and Interme-
diate Outcome Measures in COPD Study 
(SPIROMICS) is a unique longitudinal 
National Heart, Lung, and Blood Institute 
(NHLBI)-funded prospective cohort study 
designed to identify subpopulations and 
intermediate outcome measures in individ-
uals with COPD. SPIROMICS enrolled 1836 
current and former smokers with COPD 
(strata III and IV), 944 smokers without 
airflow obstruction (stratum II), and 202 
non-smoking controls (stratum I) across cities 
in the USA. The purpose of the SPIROMICS 
Air Pollution Study (SPIROMICS AIR) is 
to add state-of-the art air pollution expo-
sure assessment to estimate individual-level 
outdoor and indoor air pollution exposures 
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for all SPIROMICS participants, providing an extraordi-
nary opportunity to understand the effects of multiple air 
pollutants on COPD morbidity and progression.
METHODS
Study objectives and study design
SPIROMICS AIR has three primary objectives: (1) to 
analyse the impact of outdoor and indoor air pollutants, 
including particulate matter with aerodynamic diam-
eter less than 2.5 µm (PM2.5), nitrogen dioxide (NO2), 
nitrogen oxides (NOx), sulfur dioxide (SO2), ozone 
(O3), black carbon (BC) and second-hand smoke on 
COPD morbidity over 3 years; (2) to determine whether 
short-term changes in outdoor air pollution concentra-
tions (PM2.5, NO2) are associated with day-to-day changes 
in COPD morbidity (respiratory symptoms, risk of exac-
erbations); and (3) to examine airway macrophage 
(AM) BC content from induced sputum as a potential 
biomarker of traffic-related air pollution (PM2.5 and BC) 
and determine its association with clinical and subclinical 
measures of disease severity and progression in individ-
uals with COPD.
Each objective involves rigorous, participant-specific 
characterisation of air pollution exposures. Cohort-spe-
cific air monitoring was conducted to support the 
development of air pollution prediction models that can 
be generalised to the study population over the course 
of follow-up. These models are based on sophisticated 
spatio-temporal air pollution prediction methods devel-
oped in Multi-Ethnic Study of Atherosclerosis and Air 
Pollution (MESA Air)3 that incorporate the study-spe-
cific outdoor monitoring data, nearby regulatory air 
monitoring data and geographic information about each 
location. Spatio-temporal predictions are generated as 
2-week averages, and are primarily intended to be anal-
ysed in association with chronic outcomes such as decline 
in forced expiratory volume (FEV1), patient-reported 
outcomes and frequency of exacerbation.
Daily variation in air pollutants, which are the primary 
exposure for objective 2 and necessary as validation 
metrics for objective 3, will be based on daily measure-
ments collected at regulatory agency monitoring 
locations. Daily PM2.5 and NO2 will be linked to daily symp-
toms recorded in a subset of subjects with COPD over a 
1-year period who participated in the SPIROMICS Exac-
erbation Substudy. The Exacerbation Substudy enrolled 
217 subjects and captured respiratory symptoms using a 
daily electronic diary (EXAcerbations of Chronic pulmo-
nary disease Tool (EXACT) Patient-Reported Outcome 
(EXACT-PRO))4 for up to 1 year per subject. For aim 3, 
daily measurements of BC and PM2.5, 2-week spatio-tem-
poral predictions of BC and PM2.5, and proxies of traffic 
exposure such as distance between the residence and the 
nearest major road will be compared with AM BC. AM BC 
will be assessed in up to 1000 participants with acceptable 
quality of induced sputum collected at baseline.
The institutional review boards of all the participating 
institutions approved the study protocols.
Study population
Subjects for SPIROMICS were enrolled, phenotyped and 
followed at multiple clinical centres (Winston-Salem, 
North Carolina; Ann Arbor, Michigan; San Francisco, 
California; Los Angeles, California; New York City (NYC), 
New York; Salt Lake City, Utah; Baltimore, Mary-
land; Denver, Colorado; Iowa City, Iowa; Birmingham, 
Alabama; Chicago, Illinois; and Philadelphia, Pennsyl-
vania) from 2010 through 2016. Participants were 40–80 
years of age at baseline, who were either healthy persons 
with a smoking history of ≤1 pack-year and no known 
current lung disease (n=202) or current or former 
smokers (≥20 pack-years) with and without evidence of 
obstructive lung disease. Current and former smokers 
were categorised as having either no spirometric evidence 
of airflow obstruction (n=941), or having COPD (post-
bronchodilator FEV1/FVC <70% with Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stage I/
II (FEV1 ≥50% predicted; n=1207)) or GOLD stage III/
IV (FEV1 <50% predicted; n=624) disease. Current or 
former smokers with a concomitant diagnosis of asthma 
were not excluded, but individuals with other non-COPD 
obstructive lung disease, body mass index (BMI) >40 kg/
m2 at baseline or diagnosis of unstable cardiovascular 
disease were excluded. Individuals with prior history of 
chest surgery or metallic implants in the thorax were 
excluded due to impact on chest CT interpretation.
SPIROMICS also includes substudies that greatly 
complement the goals of the current proposal. The 
Exacerbation Substudy was designed to provide novel 
insight into the biology of COPD exacerbations and uses 
a validated daily electronic tool to measure respiratory 
symptoms (EXACT; EXACT-PRO).4 This allows for the 
capture of daily respiratory symptoms as well as capture 
of symptom-based respiratory exacerbations that may not 
have led to ‘traditional’ healthcare utilisation-defined 
events.
Clinical phenotyping and data collection
Clinical data
Clinical data were collected as part of the main 
SPIROMICS study. Spirometry before and after bron-
chodilator was performed according to standard 
guidelines5; all pulmonary function tests were monitored 
for quality control and assurance. Exacerbations were 
assessed prospectively by quarterly phone calls and yearly 
visits. Any exacerbation was defined as worsening respi-
ratory symptoms requiring antibiotics or oral steroids. 
Severe exacerbations were those leading to an emer-
gency department visit or hospitalisation. Hospitalised 
events, mortality and cause of death will be adjudicated 
by the Morbidity and Mortality Subcommittee. Additional 
patient-reported outcomes included health status deter-
mined using the St. George’s Respiratory Questionnaire6 
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and COPD Assessment Test.7 Dyspnoea was assessed 
using the Modified Medical Research Council Dyspnea 
Scale8 and functional exercise capacity was assessed by 
the 6 min walk test, performed according to American 
Thoracic Society (ATS) criteria.9 These measures were 
collected annually for up to 3 years. In addition, at the 
baseline and 1-year follow-up study visits, participants 
underwent whole-lung multidetector helical CT at full 
inspiration and expiration for measurements including 
per cent emphysema (% Hounsfield units (HU) <950 at 
total lung capacity), per cent gas trapping (%HU <856 at 
residual volume and airway dimensions (Pi10 averaged 
for the whole lung and over a sequence of five airway 
segments)) following a highly standardised protocol.10
BC in AMs
Preserved induced sputum cytospin slides have been 
collected as part of the SPIROMICS study. Cytospin 
samples were prepared from whole sputum samples that 
were treated with dithiothreitol (0.1%), filtered, then 
stained with trypan blue and counted on a haemocytom-
eter to determine the total viable leucocytes present in 
the sample. Cytospin slides were generated, fixed and 
stained for microscopic examination of leucocyte popu-
lations. Acceptable quality slides will be chosen for BC 
analysis based on evidence of good cell morphology 
(minimal cell degeneration), minimal cell debris, good 
quality staining, satisfactory cell dispersion and minimal 
squamous epithelial cell contamination. AMs will be 
visualised by light microscopy at ×100 magnification. 
Briefly, 50 AMs per slide will be randomly selected by a 
trained technician blinded to environmental exposure 
assessments and clinical outcomes and the area occupied 
by black material (carbon) in each macrophage will be 
quantified as previously described.11 12
Air quality assessment and environmental data collection
Residential address history and geocoding
The main SPIROMICS study collected a 10-year residen-
tial history at baseline and obtained address changes 
during quarterly follow-up calls and annual clinic visits. 
Addresses were geocoded at the University of Wash-
ington using ArcGIS 10.3, which preferentially places 
addresses according to parcel data (property delineation 
data). Addresses not matched to a parcel may be esti-
mated using an automated procedure which calculates 
the location of a house number. If no house number is 
available, then the address is given the location of the 
nearest intersection or middle of the length of the street. 
Failing one of these methods, the residence is placed at 
the zip code centroid. Since automated geocoding typi-
cally places locations on the centreline of roads, a 9 m 
offset was applied.13 Addresses not able to be placed at 
any of these locations are not given a location and were 
omitted from subsequent analyses.
Housing characteristics and time-location behaviour
A Home Information Questionnaire (HIQ) was adminis-
tered to each participant once during the study either in 
person or over the phone during a routine follow-up visit 
or call. The questionnaire is modified from the MESA 
Air HIQ14 and includes questions about predictors of 
indoor air pollution, which assess building characteris-
tics, heating and air conditioning use, window opening 
behaviours, indoor air pollution sources, use of combus-
tion sources and time-location patterns. The HIQ has 
previously been shown to have good agreement with a 
behaviour log administered at the time of home air moni-
toring.15
Environmental data and air pollution model predictions for 
chronic outcomes
Outdoor concentrations of PM2.5, NO2, NOx, O3, SO2 
and BC outside of each participant's home are estimated 
using spatio-temporal modelling methods developed in 
MESA Air.16 17 Briefly, long-term air pollution trends are 
estimated from measurements collected at United States 
Environmental Protection Agency (EPA) Air Quality 
System (AQS) monitoring sites and other long-term moni-
toring locations. Partial least squares regression (PLSR) 
is used to create covariates that combine geographic vari-
ables including land use, distance to roadways, vegetative 
cover, impervious surface cover, traffic data, popula-
tion and elevation. Spatially varying coefficients for the 
time trends are estimated using these PLSR covariates 
and spatial smoothing, essentially predicting the long-
term mean and scale of temporal variation based on 
point-specific characteristics. The model benefits from 
spatially rich supplemental monitoring data that are 
leveraged to estimate the spatially varying coefficients 
and determine the structure of the spatio-temporal 
residual field. These data include the cohort-focused 
monitoring conducted by SPIROMICS AIR, pollutant 
concentrations previously measured by the MESA Air 
study in the four overlapping regions (Baltimore, NYC, 
Los Angeles and Winston-Salem), and those measured by 
the New York City Community Air Study.14 18 Two types of 
outdoor air monitoring were performed in SPIROMICS 
Air cities: (1) community ‘snapshot’ and (2) residential. 
These methods allow additional spatial coverage relevant 
to this cohort not available from existing datasets.
Community ‘snapshot’ monitoring
Community ‘snapshot’ monitoring was conducted in 
each of two seasons in three of the primary study regions 
(Ann Arbor, San Francisco, Salt Lake City) to capture 
small-scale spatial variations in pollutant concentra-
tions while minimising temporal confounding. In the 
four communities previously monitored in MESA Air 
(Los Angeles, NYC, Baltimore, Winston-Salem), one 
monitoring campaign was performed to confirm spatial 
stability and understand secular trends in exposures. 
These ‘snapshot’ sampling events (table 1) include 
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simultaneous deployment of passive air monitors at 100 
locations, which are selected to oversample local sources 
of traffic, and placed on stationary objects such as tele-
phone poles adjacent to major roadways. This sampling 
effort provides integrated 2-week samples of NO2, NOX, 
SO2 and O3.
Residential monitoring
At subsets of approximately 30 participants’ residences 
in each of the seven primary SPIROMICS study regions 
(220 locations total), 2-week integrated measurements 
were collected inside and outside participants’ homes. 
We measured outdoor concentrations of PM2.5 and BC 
using active sampling, and NO2, NOx, O3 and SO2 using 
passive monitoring.19 Participants also wore passive 
samplers for NO2, NOx, O3 and SO2 to inform the compa-
rability of home exposure to total exposure.
Environmental data for daily symptoms and exacerbations
Short-term pollutant exposures are estimated as the 
concentration measured at a central site within the EPA 
AQS network on the day prior, 2 days prior and 3 days 
prior to the patient-reported acute outcomes.
Assessment of relationship between exposures and 
respiratory health
For objective 1, longitudinal analysis will test the effect 
of outdoor and indoor pollutant exposures on health 
outcomes with the primary outcome of interest being 
rate of change of FEV1 over the study period. The 
outcome will be treated as a normal random variable 
and a linear generalised estimating equation model with 
exchangeable correlation will be used to relate it to air 
pollutants and potential confounders while accounting 
for within-person variation. Additional outcomes will 
include exacerbations, mortality, CT phenotypes, 
health status and other patient-reported outcomes. 
Models will be constructed with and without adjust-
ment for potential confounders, which will include 
social factors (eg, socioeconomic status) and baseline 
predictors that have previously been shown to explain 
variability in the health outcomes, including sex, age 
and study site. Time-varying covariates will include mete-
orological factors (temperature, humidity), seasons of 
sampling, smoking status, medication use and addi-
tional exposures such as occupational exposures. Effect 
modification will be explored by including interaction 
terms in the primary regression models. For example, 
smoking status will be analysed as a confounder and 
potential effect modifier.
For the study of short-term association of air pollution 
with exacerbations and symptoms, log-linear Poisson-dis-
tributed lag-time series models will be used to estimate 
the association between pollution and health. We will 
focus on 0–3 day lags of exposure as previous work in 
this area has suggested this is where health effects tend 
to be concentrated.20 In addition to person-specific 
confounder variables, visit-specific potential confounders 
such as season, ambient temperature and humidity will 
be included. Active smoking status and intensity will be 
analysed as confounders and potential effect modifiers.
Table 1 Timeline for environmental monitoring of the SPIROMICS Air Study from 2013 to 2016
2013 2014 2015 2016
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Clinical data and questionnaires
SPIROMICS enrolment (n=2982)
Visit 2 (n=2350)
Visit 3 (n=1492)
Visit 4 (n=894)
HIQ administered (n=1938)*
Environmental monitoring
Baltimore
LA
SLC SLC
SF SF
NYC
AA AA
W-S
Sites: AA (Ann Arbor, Michigan); LA (Los Angeles, California); NYC (New York City, New York); SF (San Francisco, California); SLC (Salt Lake 
City, Utah); W-S (Winston-Salem, North Carolina).
*HIQ administered once to each participant by in-person or telephone interview. 1936 is the total number administered as of 1 September 
2016.
HIQ, Home Information Questionnaire; SPIROMICS, Subpopulations and Intermediate Outcome Measures in COPD Study.
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Analysis of AM BC as an exposure biomarker
We will examine the relationship between BC content of 
AMs and our modelled individual exposure to both PM2.5 
and BC, and then investigate the association between 
BC content of AM and health outcomes. Associations 
between modelled exposures and AM measurements will 
be adjusted for factors such as age, sex, race/ethnicity, 
severity of illness, time since last exacerbation, meteo-
rology, smoking and BMI. Clinical outcomes of interest 
include lung function, quantitative CT phenotypes and 
patient-reported outcomes. To explore possible effect 
modification, we will conduct stratified analysis by disease 
severity.
DISCUSSION
SPIROMICS AIR will use state-of-the-art exposure assess-
ment methodologies in order to understand the effect 
of outdoor and indoor air pollution on the long-term 
progression of COPD, short-term day-to-day variability in 
symptoms, and evaluate a potential sputum biomarker of 
exposure and disease. This study is needed due to the 
large degree of uncertainty regarding the potential rela-
tionship between exposure to air pollution and COPD 
progression, symptoms and quality of life.
Outdoor air pollution has been linked to exacerba-
tions and mortality in people with chronic respiratory 
disease.21 22 Population-based studies suggest that outdoor 
PM concentrations are associated with a more rapid 
decline in lung function,23 greater per cent emphy-
sema24 and an increase in COPD hospitalisations and 
mortality,20 25 and outdoor NO2 concentrations are linked 
to increased risk of developing COPD and higher rates of 
exacerbations.25–28 A study of 399 subjects with COPD due 
to alpha-1 proteinase inhibitor deficiency suggested that 
a 10 µg/m3 increase in PM10 was associated with an extra 
30 mL/year decline in FEV1.
29 Whether these findings 
extend to patients with COPD without alpha-1 proteinase 
inhibitor deficiency and whether the association of PM 
is modified by other clinical or environmental factors 
are unknown. SPIROMICS AIR allows for the longitu-
dinal assessment of the effect of air pollution on COPD 
progression on a variety of outcomes, including validated 
COPD-specific outcomes, while allowing for adjusting 
and testing of effect modification by a variety of factors.
In addition to studying effects of long-term exposure 
to outdoor air pollution on progression of COPD, short-
term effects are also still uncertain as existing studies 
investigating short-term variation in pollution and COPD 
morbidity have been inconsistent and interpretations 
limited by small sample size. For example, some studies 
have shown a link between pollutant exposures and 
decreased FEV1 or peak expiratory flow
21 22 30 whereas 
others have not.26 31 Similarly, the effect of short-term 
variability in pollutants on exacerbations and respira-
tory symptoms also remains unclear. In 94 subjects with 
COPD, higher PM10 concentrations were linked to more 
dyspnoea and exacerbations, but no consistent associa-
tion was found for other symptoms and no associations 
were found for other pollutants, including NO2, O3 or 
SO2.
26 Another panel study including subjects with COPD 
and asthma showed adverse respiratory health effects 
that included respiratory symptoms of coarse PM but not 
PM2.5 or NO2.
32
Studies assessing risk of exacerbations have relied 
on defining exacerbations by healthcare events such as 
prescription of systemic corticosteroids, antibiotics or 
unscheduled visits to a healthcare provider. However, 
using an event-based definition may miss a significant 
number of COPD exacerbations that are unreported but 
nonetheless are associated with worsening symptoms and 
health status.33 In addition, previous published studies 
suggest that a lag of 1–3 days may exist between increasing 
pollutant concentrations and risk of an exacerbation34; 
however, it is known that COPD exacerbations follow 
distinct, but varying, patterns of onset and recovery.35 We 
will investigate whether short-term changes in outdoor 
air pollution (PM2.5, NO2) are associated with day-to-day 
changes in COPD symptoms among the subset of subjects 
enrolled in the SPIROMICS exacerbations substudy. 
Given the extensive clinical characterisation afforded by 
SPIROMICS, we will be uniquely positioned to examine 
the time course of pollutant exposure and the initial onset 
as well as trajectory of symptom development leading to a 
reported exacerbation. Similarly, we will explore whether 
pollutant concentrations affect the varying courses of 
symptom improvement following exacerbations.
In addition to advancing our understanding of 
outdoor air pollution on variability of COPD symptoms 
and COPD progression, SPIROMICS AIR will aim to 
investigate the effects of indoor air pollution on COPD. 
Americans, particularly older individuals, spend the 
vast majority of time indoors (87%),36 and individ-
uals with COPD spend more time at home than their 
age-matched counterparts.37 Even in homes where 
biomass is not used as a heating or cooking source, 
indoor PM2.5 concentrations may be associated with 
worse health status,38 and among former smokers with 
moderate-severe COPD living in the Baltimore–Wash-
ington area, indoor PM2.5 concentrations were shown 
to be associated with increases in COPD morbidity.39 
Importantly, indoor air pollution is due to both indoor 
pollutant sources and to infiltration of outdoor air 
pollutants. Using the individual residential characteris-
tics collected from the home information questionnaire 
completed by the majority of SPIROMICS participants 
in combination with meteorological data, we will be able 
to predict home infiltration efficiency, and predict 
indoor concentrations regardless of the region of resi-
dence. Understanding the potential role of indoor air 
pollution on COPD outcomes at the individual level 
is particularly important for indoor air since, unlike 
outdoor air, it can be modified. This would allow 
disease management strategies to emphasise reduction 
of pollutant exposure in the patient’s home.
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As we characterise the role of outdoor and indoor 
air pollution in contributing to COPD outcomes and 
progression, it becomes increasingly important to 
identify potential biomarkers of pollutant exposure. 
Black-pigmented material in airway macrophages (AM) 
is carbonaceous in nature, and recent literature suggests 
that a dose–response relationship may exist between this 
biomarker and PM exposure in healthy controls.11 40 In 
addition, recent work by Belli et al suggests that BC in AM 
found in induced sputum may be highly correlated with 
indoor, but not outdoor, PM in subjects with COPD.12 
It remains to be shown whether the carbon content of 
AMs reflects long-term or short-term exposure to PM and 
what is the relative contribution of different exposures 
to AM BC content. The accumulation of BC may lead to 
inflammation, double-stranded DNA breaks and emphy-
sema in mice,41 and may at least partly explain adverse 
health outcomes of pollution seen in smokers and 
non-smokers. Access to banked sputum samples as part 
of SPIROMICS permits an unprecedented evaluation of 
this novel measure as a biomarker of pollution exposure.
In summary, the NHLBI-funded SPIROMICS observa-
tional study, combined with state-of-the-art air pollution 
exposure assessment methods, provides an extraordinary 
opportunity for groundbreaking advances in under-
standing the contribution of environmental factors to 
COPD progression and disability.
SPIROMICS AIR will have the benefit of being able 
to link modelled pollutant concentrations to the exten-
sive participant data collected as part of the SPIROMICS 
study, enabling the exploration of underlying mecha-
nistic underpinnings to the adverse outcomes resulting 
from pollution exposure in individuals with COPD.
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